you sound like a real windbag. btw, looks like no news for a few weeks. they are appearing at the needham conf. you don't announce big news before one brokerage conf.
keep dreaming... its down
stock looks like a secondary coming
lol do you really think your posts can control the share price?
I have an idea, use your left hand and pretend it's someone else.
The most interesting piece of data we saw was Nimbus’ NDI-010976. Gilead acquired the rights to the drug recently for $400 million upfront and $800 million in potential milestones. We now see why Gilead wanted the drug. NDI-010976 is an acetyl-CoA carboxylase (ACC) inhibitor. ACC is a critical enzyme in fatty acid metabolism. The drug blocks fatty acid synthesis, lowers tissue triglycerides, and increases fatty acid oxidation and insulin sensitivity. In a dose-finding study, Nimbus was able to inhibit de novo lipogenesis in a dose-dependent fashion. At the high dose (200 mg), the drug completely blocked de novo lipogenesis. In other words, it succeeded in taking the fat out of the fatty liver. If there are no untoward side effects in larger and longer studies, this approach promises to be a potent mechanism of action in reversing fatty liver (NAFLD), and potentially halting the disease progression from NAFLD to NASH to cirrhosis. The frustration in the field has been that the drugs currently in late-stage trials for NASH – be they OCA (ICPT) or dual PPAR (GNFT.PA) – are limited in efficacy This ACC inhibitor may be different.
the collaboration on neurological diseases (hopefully no platelet issue yet) may lead to a corporate transaction. This is where BIIB is going as they are spinning off their hemophilia franchise.
In a new study, published online June 6 in Nature, researchers at University of California San Diego School of Medicine and Moores Cancer Center, together with colleagues at Keio University, the University of Nebraska and Ionis Pharmaceuticals describe an innovative new model that not only allowed them to track drug resistance in vivo, but also revealed a new therapeutic target, which early testing suggests could provide a strategy to arrest pancreatic cancer growth.